A Study to Evaluate Real World Outcomes of the enVista® Aspire (EA) and Aspire Toric (ETA) Intraocular Lens in Subjects Undergoing Cataract Extraction

Completed · Not applicable

Conditions studied: Cataract

In brief

A study to evaluate the real-world clinical performance of the enVista Aspire and Aspire Toric intraocular lens (IOL) models EA and ETA and to assess surgeon and subject satisfaction

Key facts

Study ID

NCT06594185

Run by

Bausch & Lomb Incorporated

People needed

335

Starts

2024-08-29

Expected to finish

2025-05-21

Last updated by the study team

2026-06-03

Who can join

Age: 22 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 22 years of age or older on the date the Informed Consent Form (ICF) is signed.
• Subjects must be capable of understanding and providing informed consent on the Institutional Review Board (IRB)- approved Informed Consent Form (ICF) and authorization as appropriate for local privacy regulations.
• Have a BCDVA at or worse than 20/40 in each eye, with or without a glare source, due to a clinically significant cataract (cortical, nuclear, subcapsular, or combination) that is considered amenable to treatment with standard phacoemulsification cataract extraction and capsular IOL implantation.
• Have a BCDVA projected to be better than 20/30 after IOL implantation in each eye as determined by the medical judgment of the Principal Investigator.
• Subjects must have clear intraocular media other than the cataract in both eyes.
• Subjects must require an IOL power from +6.0 diopter (D) to +34.0 diopter (D) in both eyes.
• Subjects with clinically significant preoperative corneal astigmatism must require an IOL toric power between 1.25 diopter (D) to 5.75 diopter (D).
• Subjects must be willing and able to comply with all treatment and follow-up Clinical Investigation visits and procedures

You may not qualify if…

• Pre-existing ocular conditions (subjects with prior corneal refractive surgery, irregular corneal astigmatism, severe (clinically significant) corneal dystrophy, e.g., Fuch's, macular disease, optic nerve atrophy, corneal endothelial disease, abnormal cornea, macular degeneration, retinal degeneration, and chronic drug miosis, who may not achieve the visual acuity of patients without such problems, etc.)
• Associated ocular conditions that could affect the stability of the IOL (e.g., traumaticzonulolysis, zonular dialysis, evident zonular weakness or dehiscence, etc.) in the study eye.
• Retinal conditions, or predisposition to retinal conditions, previous history of, or a predisposition to, retinal detachment or proliferative diabetic retinopathy, in which future treatment may be compromised by implanting this IOL
• Amblyopia
• Rubella, congenital, traumatic, or complicated cataracts
• Extremely shallow anterior chamber, not due to swollen cataract
• Recurrent anterior or posterior segment inflammation of unknown etiology, or any disease producing an inflammatory reaction (e.g., iritis or uveitis)
• Aniridia
• Iris neovascularization
• Subjects who have uncontrolled glaucoma in either eye. Uncontrolled glaucoma is defined as intraocular pressure (IOP) greater than 21 mm Hg in spite of maximally tolerated medications (with more than three topical drugs for IOP control).
• Microphthalmos or macrophthalmos
• Previous corneal transplant, prior YAG laser iridotomy, YAG vitreolysis, and prior phakic IOL insertions.
• Pre-existing ocular conditions that may negatively impact the stability of the implant or intraoperative conditions (posterior capsular rupture, complications in which the IOL stability could be compromised, inability to place IOL in capsular bag, etc.).
• Mechanical or surgical manipulation required to enlarge the pupil
• Vitreous loss (significant)
• Anterior chamber bleeding (significant)

Where it is running

• Site 154 — Bullhead City, Arizona, United States
• Site 137 — Chandler, Arizona, United States
• Site 136 — Mesa, Arizona, United States
• Site 162 — Phoenix, Arizona, United States
• Site 105 — Tucson, Arizona, United States
• Site 104 — Bakersfield, California, United States
• Site 101 — Beverly Hills, California, United States
• Site 151 — Hemet, California, United States
• Site 111 — Huntington Beach, California, United States
• Site 126 — Long Beach, California, United States
• Site 149 — Los Angeles, California, United States
• Site 155 — Murrieta, California, United States
• Site 109 — Newport Beach, California, United States
• Site 112 — Orange, California, United States
• Site 144 — Pasadena, California, United States
• Site 119 — Torrance, California, United States
• Site 115 — Upland, California, United States
• Site 161 — Greenwich, Connecticut, United States
• Site 130 — Milford, Connecticut, United States
• Site 164 — Stamford, Connecticut, United States
• Site 125 — Bradenton, Florida, United States
• Site 148 — Mt. Dora, Florida, United States
• Site 143 — Pompano Beach, Florida, United States
• Site 127 — Tarpon Springs, Florida, United States
• Site 118 — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.